A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. - Wikidata - wikimedia - TriplyDB

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

http://www.wikidata.org/entity/Q35384561

about

Liver transplantation for viral hepatitis in 2015 Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in Hepatitis C: New challenges in liver transplantation Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver Transplantation Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy.Current Issues in Liver Transplantation.Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals.Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.Management of post transplant hepatitis C in the direct antiviral agents era.Treatment of hepatitis C in difficult-to-treat patients.Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation.Management of Post-Liver Transplant Recurrence of Hepatitis C.Developing therapies to treat hepatitis C infection in post-liver transplant recipients.Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study.Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation.Outcomes of spontaneous bacterial peritonitis in liver transplant recipients with allograft failure.Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience.Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.Post-liver transplant hepatitis C therapy.Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.Sofosbuvir and Ribavirin for 24 Weeks Is An Effective Treatment Option for Recurrent Hepatitis C Infection After Living Donor Liver Transplantation.High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.Beyond the achievement of sustained virological response after liver transplantation.Effectiveness and safety of sofosbuvir/ledipasvir ± ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience.

P2860

Q26773224-C381209C-07EC-4C1F-866F-1EE33A375E46 Q26781331-53D01F3F-7326-4C4F-9848-F393FC396C11 Q26781741-AEB7F099-EE54-4A18-8B7E-22B23011506B Q26781984-8BED7369-24E9-4F77-BAED-48EA538D8773 Q26820811-8A5F8719-23D1-41F5-98C4-25F323F075A3 Q26999368-33AB38B5-0B9D-43A8-9FA2-0E837CE410D2 Q33423299-ACCB6B22-34B2-48CD-B15F-DC0651C84659 Q33426112-93DC7FBF-AC0E-495E-9B46-AE5B40802549 Q36241697-34884C23-5908-44B4-9643-D44EC822D082 Q36716620-8E94A29D-B543-4D8A-9288-A028566D8522 Q36760075-0A2629E6-FB67-4F0C-BD4D-85069605EBF0 Q36855565-89345D6A-9B81-42A6-8848-4242A95DA0EA Q36916657-366CDC24-5A0C-4773-8FF7-20D55CA2DF5B Q37552703-67C01363-3F0F-43F8-A015-2E4A23383A39 Q38265900-830218A8-C81C-4DE0-98E7-A58A36A78313 Q38384095-B568D08C-B3C9-49E6-825B-1546678C51CB Q38395275-B91EA9E1-40F5-45F8-9629-BE6279E21FC1 Q38431523-E17C31FF-6611-4A56-87DE-429802DB6180 Q38769679-E4C4E0AC-E12F-4E77-83DA-CDB407BEB1FB Q38976820-708CEB0E-8E2A-4FC6-863B-2446D01E2E7D Q39017681-F3A9C9FD-C9D7-4C0A-8834-3BC3F52A0D04 Q39055696-056250B2-3141-4B62-AB2C-E590B8DBC107 Q39471334-1CF2D084-C7EC-46FA-8102-E0BE7F0C087A Q39612358-5CDC9EF1-5298-4B68-AD43-81A90C41E7CB Q40107697-961653AA-BFF5-4154-8D26-1168D50DDB3D Q40584810-36F09F0E-6FAE-4B3F-909E-59A84A58040F Q40645895-F7A43D14-E214-4A81-BF2E-2CABFED28245 Q40705980-191716F5-8047-4651-AE0C-6A8601A4C82F Q40896916-3ACB4EB8-FDAD-43BB-ACE2-A5E49DCF2735 Q41006072-86957AC0-7982-42E9-9A56-70DA49B63A0C Q41383820-25305E2C-B48B-4E39-AC9B-6DCEA14D7521 Q41461491-CFD64D88-2A4D-4B6A-A799-D432CBCD8341 Q41925906-C872F87D-D6A9-45C1-9757-908089996921 Q42213969-11AF91CA-5139-41EC-8627-7EBC9B6E43F7 Q50992708-F5093319-DFA5-4B6C-A1E2-3B1CC0EECADE Q55407931-7B35C040-265F-439A-AA30-B2D2B39BDA51

P2860

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.

http://www.wikidata.org/entity/Q35384561

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@ast

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@en

type

label

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@ast

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@en

prefLabel

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@ast

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@en

P1433

Q35384561-993C65AE-2BCA-4EDF-89EA-37EF79834151

P1476

Q35384561-F046B13A-ACF6-4D4A-9881-ED4768741A89

P2093

Q35384561-1AE0A2EA-2744-47F4-94B2-AAF15B0C00AC

Q35384561-ACCBC3A7-642A-4014-9529-07CB31D638FD

Q35384561-B27AFDE3-D9AF-426E-BB2D-5EF592FE613F

Q35384561-B2C71509-D0B5-4C39-B632-032FB978C7A7

Q35384561-BF2BF3CA-1711-4298-AEA1-715062BD6916

Q35384561-C457C459-A7D1-4784-8ED8-A4BD8B4A8857

Q35384561-D6469866-ADC1-47D4-AB3A-C86C6292D9AE

Q35384561-E5033094-5F75-488E-B5A1-CCC9017375A1

Q35384561-E87932A0-65DA-40E9-AF50-4CD0DD78EB54

Q35384561-F194B0A9-ECEB-46E6-9DEB-A821E0E45696

P2860

Q35384561-0C20A594-2774-4615-AD0C-7834B0180633

Q35384561-0E36DF61-733D-4AC6-B4FA-5AC002087F07

Q35384561-0FC92FDB-C3DC-4595-B4E5-95514D6DFEE2

Q35384561-19553616-9D6E-42F6-9808-13FC1BC93E40

Q35384561-1EC3D079-E708-4BE6-B1B5-53B98A76EF4F

Q35384561-3EABD422-A2F7-4BA9-B795-06A8B7FDBB77

Q35384561-47F67CF6-FA05-4F17-B7AA-056D9766BA79

Q35384561-4E581B51-6779-4EDE-A874-0155DBF454C8

Q35384561-507E40CE-D674-4502-BB12-E9132341796A

Q35384561-57D64005-899F-4FF1-89E6-3C5426BFFF9E

P304

Q35384561-A45590E4-AB41-4265-BF27-5B6E9D1F6979

P31

Q35384561-D6152154-76D5-45FB-8D5B-55511CDE7C6B

P356

Q35384561-9C75E0CD-9D66-4AB3-85BF-DCAA46284660

P433

Q35384561-FF12A358-FB69-4A2D-87FB-8E8BA105D453

P478

Q35384561-D2782B06-F356-47C7-B127-6449DDD2E389

P577

Q35384561-499DA1D8-8C1D-43DA-BA71-A78BDA754874

P698

Q35384561-1D390626-FD71-4BA1-BFBB-41363144E9D8

P921

Q35384561-D6A60309-42C1-41CC-A6BB-3372E580F564

P932

Q35384561-591C1042-5883-40BD-99B6-FC54C93080EC

P356

J.JHEP.2014.04.037

P1433

Journal of Hepatology

P1476

A US multicenter study of hepa ...... ease-inhibitor triple therapy.

@en

P2093

Elizabeth C Verna

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

Jacqueline G O'Leary

http://www.w3.org/2001/XMLSchema#string

James F Trotter

http://www.w3.org/2001/XMLSchema#string

James R Burton

http://www.w3.org/2001/XMLSchema#string

Jennifer L Dodge

http://www.w3.org/2001/XMLSchema#string

Joshua Levitsky

http://www.w3.org/2001/XMLSchema#string

Norah A Terrault

http://www.w3.org/2001/XMLSchema#string

Richard T Stravitz

http://www.w3.org/2001/XMLSchema#string

Robert S Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

Review and management of drug interactions with boceprevir and telaprevir

Telaprevir for retreatment of HCV infection

Telaprevir for previously untreated chronic hepatitis C virus infection

Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.

Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.

Efficacy of antiviral therapy for hepatitis C after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis.

Management of HCV transplant patients with triple therapy.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

P304

508-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2014.04.037

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24801415

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4394742

http://www.w3.org/2001/XMLSchema#string